Cagent Vascular, based in Wayne, PA, is thrilled to announce a breakthrough funding round that has raised an impressive $30,000,000. This significant infusion of capital marks a pivotal moment in the company’s journey as it continues to innovate and lead the way in advanced vascular treatment technologies. Recognized for developing and commercializing its revolutionary Serranator PTA Serration Balloon Catheter, Cagent Vascular has pioneered the only angioplasty balloon with serration technology on the market. This novel device is engineered specifically to treat blocked arteries in the leg, addressing critical conditions such as Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI), thereby offering renewed hope and improved outcomes for patients battling these debilitating conditions.
The funds raised will be strategically deployed to further enhance research and development efforts, streamline production capabilities, and expand clinical trials that demonstrate the efficacy and safety of the Serranator PTA Serration Balloon Catheter in a broader patient population. Additionally, this capital will support the company’s initiatives to strengthen regulatory compliance and foster lucrative partnerships in global markets, ultimately ensuring that the innovative benefits of serration technology reach as many patients as possible. As Cagent Vascular continues to push the boundaries of vascular treatment solutions, this funding milestone not only strengthens its financial foundation but also reinforces its commitment to revolutionizing the standard of care for those affected by PAD and CLTI. The future of vascular health is brighter with Cagent Vascular leading the charge in medical device innovation.
.png&w=3840&q=75)
